Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Cash from Investing Activities (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Cash from Investing Activities data on record, last reported at -$184000.0 in Q2 2025.

  • For Q2 2025, Cash from Investing Activities changed N/A year-over-year to -$184000.0; the TTM value through Sep 2025 reached -$195000.0, down 233.56%, while the annual FY2024 figure was $34000.0, 99.89% down from the prior year.
  • Cash from Investing Activities reached -$184000.0 in Q2 2025 per SNTI's latest filing, down from -$11000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $21.1 million in Q3 2023 and bottomed at -$230.0 million in Q2 2021.
  • Average Cash from Investing Activities over 5 years is -$49.5 million, with a median of -$7.4 million recorded in 2022.
  • Peak YoY movement for Cash from Investing Activities: skyrocketed 262.8% in 2023, then plummeted 110.89% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$230.0 million in 2021, then skyrocketed by 78.64% to -$49.1 million in 2022, then surged by 100.21% to $101000.0 in 2023, then tumbled by 110.89% to -$11000.0 in 2024, then crashed by 1572.73% to -$184000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$184000.0 in Q2 2025, -$11000.0 in Q4 2024, and $60000.0 in Q3 2024.